Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Indaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer Indications

Published 19/04/2023, 16:08
Updated 19/04/2023, 17:10
© Reuters.  Indaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer Indications

© Reuters. Indaptus Therapeutics Says Antitumor Platform Demonstrates Preclinical Efficacy Across Cancer Indications

Benzinga -

  • Indaptus Therapeutics Inc (NASDAQ: INDP) announces data presented in a poster at the American Association for Cancer Research (AACR) annual scientific conference on the company's Decoy anti-tumor platform.
  • Decoy10 demonstrated a 90% reduction of LPS-endotoxin activity and the use of 100% killed, non-pathogenic bacteria.
  • Decoy10 inhibited tumor growth and metastasis and induced tumor regressions as a single agent.
  • Regressions were also seen with Decoy10 in combination with a non-steroidal anti-inflammatory drug (NSAID), an anti-PD-1 checkpoint inhibitor, low-dose chemotherapy (LDC), and LDC plus a targeted antibody.
  • Regressions were durable and associated with immunological memory-mediated rejection of tumor rechallenge.
  • In vivo anti-tumor activity was seen with colorectal, breast, hepatocellular, pancreatic carcinomas, and non-Hodgkin's lymphomas (mouse and human) in preclinical models.
  • In December 2022, the company initiated its Phase 1 dose escalation and expansion clinical trial of Decoy20 in patients with advanced solid tumors where currently approved therapies have failed.
  • The Phase 1 study has begun with a single dose escalation followed by an expansion with continuous administration of Decoy20.
  • Price Action: INDP shares are up 5.08% at $2.59 on the last check Wednesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.